Par Pharmaceutical has been given final approval from the US Food and Drug Administration to begin marketing nateglinide tablets, a generic version of Novartis’ Starlix diabetes II treatment.

Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.

Par will begin shipping the 60mg and 120mg strengths of nateglinide immediately.

According to IMS Health data annual sales of Starlix reached approximately $124m in the US.